Rethinking HFpEF: Targeting obesity as the root cause

Prof Andrew Sindone AM

writer

Prof Andrew Sindone AM

Cardiologist; Director of the Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital; Head, Department of Cardiology, Ryde Hospital

Claim CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

1 hours

These are activities that use your work data to ensure quality results.

EA
0.5 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 minutes

These are activities that require reflection on feedback about your work.

MO
1 minutes

These are activities that use your work data to ensure quality results.

New Heart Foundation consensus statement recommends considering semaglutide or tirzepatide for improved quality of life and symptoms in people with HFpEF & obesity. Here’s an overview of the research to date…

Rising obesity rates1 are contributing to an ever-growing burden of chronic disease. Beyond its well-known associations with diabetes and hypertension, obesity has now emerged as a leading driver of heart failure with preserved ejection fraction (HFpEF), a form of heart failure that has long been considered difficult to diagnose and even harder to treat.

Recent years have brought a surge in our understanding of the complex interplay between adiposity, cardiovascular mechanics, and systemic inflammation. Alongside these insights, new therapeutic strategies, including incretin-based agents, are reshaping the management of patients with obesity-related HFpEF.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

  1. Australian Institute of Health and Welfare. Overweight and obesity. Available at: https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/summary [accessed January 2026].
  2. Koskinas KC, et al. Eur Heart J. 2024;45(38):4063–4098.
  3. Khan SS, et al. JAMA Cardiol. 2018;3(4):280-287.
  4. Morgen CS, et al. Mayo Clin Proc. 2023;98(10):1458–1468.
  5. Lopez-Candales A, et al. Cardiovasc Ther. 2023;2023:1552826.
  6. Savji N, et al. JACC Heart Fail. 2018;6(8):701–709.
  7. Duca F, et al. Sci Rep. 2018;8:1080.
  8. Lam CSP, et al. Circ Heart Fail. 2012;5:571–578.
  9. Kaur & Lau. Womens Health (Lond). 2022;18:17455057221140209.
  10. Karakasis P, et al. 2024;12(9):2112.
  11. Obokata M, et al. 2017;136:6–19.
  12. Kitzman DW & Lam CSP. 2017;136:20–23.
  13. Sindone AP et al. Heart Lung Circ. 2025;34(10):1033–1040.
  14. Chockalingam A. Front Cardiovasc Med. 2022;9:821829.
  15. El Hajj EC, et al. J Am Heart Assoc. 2021;10(21):e022930.
  16. Aminian A et al. 2019;322:1271–1282.
  17. van Veldhuisen, SL et al. Eur Heart J. 2022;43(20):1955–1969.
  18. Kosiborod, MN et al. 2024;149:204–216.
  19. Kosiborod, MN et al. 2024;404(10456):949–961.
  20. Packer M, et al. N Engl J Med. 2025;392(5):427–437.
  21. Andraos J, et al. Rev Endocr Metab Disord. 2023;24(6):1089–1101.
  22. National Heart Foundation of Australia, Obesity and cardiovascular disease: A clinical consensus statement, 2026.
  23. Chopra V, et al. Heart Lung Circ. 2025;34(7):e55-e82.

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Debbie Rigby

A/Prof Debbie Rigby

Why Inhaler Device Design and Technique Matters

Dr Philip Tong

Dr Philip Tong

Facial Rashes Case Studies – Practical Guide to Assessment and Management

Dr Rupert Hinds

Dr Rupert Hinds

Abdominal Pain in Children – Practical Approach in GP

Prof Roger Chen

Prof Roger Chen

Practical Guide to Improving Control of T2D

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Andrew Sindone AM

writer

Prof Andrew Sindone AM

Cardiologist; Director of the Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital; Head, Department of Cardiology, Ryde Hospital

Test your knowledge

Recent articles

Latest GP poll

In the last twelve months, how many adverse outcomes have you encountered arising from pharmacy prescribing?

None

0%

1-2

0%

Three or more

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.